Is interferon-gamma the right marker for bacille Calmette-Guérin-induced immune protection? The missing link in our understanding of tuberculosis immunology

Clinical and Experimental Immunology

Volumn 169, Issue 3, 2012, Pages 213-219

  Abebe, F ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

BCG; Immunity; T cells; Tuberculosis; Vaccination

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; PLACEBO;

CD8+ T LYMPHOCYTE; GAMMA DELTA T LYMPHOCYTE; HUMAN; IMMUNITY; IMMUNOLOGICAL MEMORY; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; VACCINATION;

ANIMALS; BCG VACCINE; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS; TUBERCULOSIS; WORLD HEALTH;

EID: 84864744848     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04614.x     Document Type: Review

References (78)

1. World Health Organization (WHO). Global tuberculosis control: epidemiology, strategy, financing. Geneva: WHO, 2009.
2. Haries AD, Zachariah R, Cobbet EL etal. The HIV-associated tuberculosis epidemic - when will we act? Lancet 2010; 375:1906-19.
3. Wright A, Zignol M, Van Deun A etal. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009; 30:1861-73.
4. Kaufmann SH. Future vaccine strategies against tuberculosis: thinking outside the box. Immunity 2011; 33:567-77.
5. Trunz BB, Fine P, Dye C. BCG vaccination on childhood tuberculosis meningitis and miliary tuberculosis world-wide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367:1173-80.
6. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346:1339-45.
7. Golditz GA, Brewer TF, Berkey CS etal. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271:698-702.
8. Connor LM, Harvie MC, Rich FJ, Quinn KMBrinkmann V, Gros GL, Kriman JR. A key role for lung-resident memory lymphocytes in protective immune responses after BCG vaccination. Eur J Immunol 2010; 40:2482-92.
9. Orme IM. The Achilles heel of BCG. Tuberculosis (Edinb) 2010; 90:329-32.
10. Hanekom WA. The immune response to BCG vaccination of newborns. Am J Acad Sci 2005; 1062:69-78.
11. Hussey G, Hawkridge T, Hanekom W. Childhood tuberculosis: old and new vaccines. Respir Rev 2007; 8:148-54.
12. McShane H. Tuberculosis vaccines: beyond bacille Calmette-Guérin. Phil Trans R Soc B 2011; 366:2782-9.
13. Finen C, Ota MO, Marchant A etal. Natural variation in immune responses to neonatal Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccination in a cohort of Gambian children. PLoS ONE 2008; 3:e3485.
14. Fine PA, Cameiro IAM, Milstein J, Clements CJ. Issues relating to the use of BCG in immunization programmes. A discussion document. WHO/V&B/99.23, Geneva: World Health Organization, 1999.
15. Kaufmann SH. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet 2011; 11:633-40.
16. Behr MA, Small PM. A historical and molecular phylogeny of BCG strains. Vaccine 1999; 17:915-22.
17. Golditz GA, Bekey SC, Mosteller F etal. The efficacy of bacille Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analysis of published literature. Paediatrics 1995; 96:29-35.
18. Vekemans J, Lienhardt C, Sillah JS etal. Tuberculosis contacts but not patients have higher gamma interferon responses to ESAT-6 than do community controls in The Gambia. Infect Immun 2001; 69:6554-7.
19. Lalor MK, Floyd S, Gorak-stolinska P etal. BCG vaccination induces different cytokine profiles following infants BCG vaccination in UK and Malawi. J Infect Dis 2011; 204:1075-85.
20. Lalor MK, Ben-Smith A, Gorak-Stolinska P etal. Population differences in immune responses to bacille Calmette-Guérin vaccination in infancy. J Infect Dis 2009; 199:795-800.
21. Hussey G, Hawkridge T, Hanekom W. Childhood tuberculosis: old and new vaccines. Mini-symposium: childhood tuberculosis. Paediatr Respir Rev 2007; 8:148-54.
22. Mosmann TR, Cofmann RL. TH1 and TH2 cells. Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7:145-73.
23. Gor DO, Rose NR, Greenspan NS. TH1-TH2: a procrustean paradigm. Nat Immunol 2003; 4:503-5.
24. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Alternat Med 2003; 8:223-46.
25. Chaout G. Th1/Th2 paradigm: still important in pregnancy? Semin Immunopathol 2007; 29:95-113.
26. Abebe F, Bjune G. The protective role of antibody response during Mycobacterium tuberculosis infection. Clin Exp Immunol 2009; 157:235-43.
27. Roche PW, Triccas JA, Winter N. BCG vaccination against tuberculosis: past disappointments and future hopes. Trends Microbiol 1995; 3:397-401.
28. Jouanguy E, Doffinger R, Dupius S etal. IL-12 and IFN-gamma in host defence against mycobacteria and salmonella in mice and men. Curr Opin Immunol 1999; 11:346-51.
29. Flynn JL, Chan J, Triebold KJ etal. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178:2249-54.
30. Cooper AM, Adams LB, Dalton DK etal. IFN-gamma and NO in mycobacterial disease: new jobs old hands. Trends Microbiol 2002; 10:221-6.
31. Chan J, Xing Y, Magliozzo RS etal. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 1992; 175:1111-22.
32. McMicking JD, Taylor GA, McKinney JD. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 2003; 24:654-9.
33. Yates RM, Hermetter A, Talor GA, Russel DG. Macrophage activation down-regulates the degradative capacity of the phagosome. Traffic 2007; 8:241-50.
34. McKinney JD, Honer Zu Bentrup K, Munoz-Elias EJ etal. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000; 406:735-8.
35. Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 2006; 441:890-3.
36. Bourgeois C, Rocha B, Tanchot C. The role of CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 2002; 297:2060-3.
37. Zhu J, Paul WE. Heterogeneity and plasticity of T helper cells. Cell Res 2010; 20:4-12.
38. Siegrist C-A. Chapter 2, section 1: General aspects of vaccination. Available at:
39. Mittrucker H-W, Stenhoof U, Kohler A etal. Poor correlation between BCG vaccination-induced T cell response and protection against tuberculosis. Proc Natl Acad Sci USA 2007; 104:12434-124.
40. Cowley SC, Elkins KL. CD4+ T cells mediate IFN-γ-independent control of Mycobacterium tuberculosis infection both in vitro and in vivo. J Immunol 2003; 171:4689-99.
41. Kagina BMN, Abel B, Scriba TJ etal. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med 2010; 182:1073-9.
42. Scanga CA, Mohan VP, Yu K etal. Depletion of CD+T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon-γ and nitric oxide synthase 2. J Exp Med 2000; 192:347-58.
43. Caruso AM, Serbina N, Klein E etal. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-γ, yet succumb to tuberculosis. J Immunol 1999; 162:5407-16.
44. Cooper AM, Flynn JL. The protective immune response to Mycobacterium tuberculosis. Curr Opin Immunol 1995; 7:512-16.
45. Ladel CH, Daugelat S, Kaufmann SHE. Immune response to Mycobacterium bovis bacille Calmette-Guérin infection in major histocompatibility complex class I and class II-deficient knockout mice: contribution of CD4 and CD8 T cells to acquired resistance. Eur J Immunol 1995; 25:377-84.
46. Abou-Zeid C, Gares MP, Inwald J etal. Induction of a type I immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae. Infect Immun 1997; 65:1856-62.
47. Hoft DF, Worku S, Kampmann B etal. Investigation of the relationship between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity. J Infect Dis 2002; 186:1448-57.
48. Soares AP, Scriba TJ, Joseph S etal. Bacille Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotype profiles. J Immunol 2008; 180:3569-77.
49. Ting LM, Kim AC, Cattamanchi A etal. Mycobacterium tuberculosis inhibits IFN-γ activation of STA1. J Immunol 1999; 163:3898-906.
50. Dupius S, Dargemont C, Fieschi C etal. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 2001; 293:300-3.
51. Abebe F, Mustafa T, Nerland AH, Bjune G. Cytokine profile during latent and slowly progressive primary tuberculosis: a possible role for interleukin-15 in mediating clinical disease. Clin Exp Immunol 2006; 143:180-92.
52. Doherty M, Wallis RS, Zumla A. Biomarkers for tuberculosis disease status and diagnosis. Curr Opin Pulm Med 2009; 15:181-7.
53. Bennekov T, Dietrich J, Rosenkrnds I etal. Alteration of epitope recognition pattern in Ag85 and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis. Eur J Immunol 2006; 36:3346-33.
54. Netea MG, Quintin J, van der Meer JWM. Trained immunity: a memory for innate host defence. Host Cell Microbe 2010; 19:355-61.
55. Sun JC, Lanier L. NK cell development, homeostasis and function: parallels with CD8+ T cells. Nat Rev 2011; 11:645-57.
56. Meraviglia S, EL Daker S, Dieli F etal. γδ T cells cross-link innate and adaptive immunity in Mycobacterium tuberculosis infection. Clin Dev Immunol 2011; 78:1-11.
57. Girardi M. Immunosurveillance and immunoregulation by γδ T cells. J Invest Dermatol 2006; 126:25-31.
58. Yanis EM, Kaufmann SH, Schwartz RH, Pardoll DM. Activation of gamma delta T cells in the primary immune response to Mycobacterium tuberculosis. Science 1989; 12:713-16.
59. Tanaka Y, Sano S, Nieves E etal. Non-peptide ligands for human γδ T cells. Proc Natl Acad Sci USA 1994; 9:8175-9.
60. Kabelitz D, Bender A, Prospero T etal. The primary response of human γ/δ T cells to Mycobacterium tuberculosis is restricted toVγ9-bearing cells. J Exp Med 1991; 173:1331-8.
61. Wu Y, Wu W, Wong WM etal. Human gamma delta T cells: a lymphoid lineage cell capable of professional phagocytosis. J Immunol 2009; 183:5622-9.
62. Dieli F, Troye-Blomberg M, Ivanyi J etal. Granulysin-dependent killing of intracellular and extracellular Mycobacterium tuberculosis by V-γδ9/γδ2 T lymphocytes. J Infect Dis 2001; 184:1082-5.
63. Ismaili J, Olislagers V, Poupot R etal. Human γδ T cells following intranasal infection with Mycobacterium bovis bacille Calmette-Guérin. J Immunol 2002; 103:296-302.
64. Lockert E, Green AM, Flynn JL etal. IL-17 production is dominated by γδ T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 2006; 177:4662-9.
65. Umemura M, Yahagi A, Hamada S etal. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guérin infection. J Immunol 2007; 178:3786-96.
66. Wozniak TM, Saunders BM, Ryan AA, Britton WJ. Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon. Infect Immun 2010; 78:4187-94.
67. Flynn JL. Immunology of tuberculosis and implications in vaccine development. Tuberculosis 2004; 84:93-101.
68. Dong Y, Demaria S, Sun X etal. HLA-A2-restricted CD8+-cytotoxic-T-cell responses to novel epitopes in Mycobacterium tuberculosis superoxide dismutase, alanine dehydrogenase, and glutamine synthetase. Infect Immun 2004; 72:2412-15.
69. Kawashima T, Norose Y, Watanable Y etal. Cutting edge: major CD8 T cell response to live bacillus Calmette-Guérin is mediated by Cd1 molecules. J Immunol 2003; 170:5345-8.
70. Sousa AO, Mazzaccaro RJ, Russel RG etal. Relative contributions of distinct MHC class I-dependent cell populations in protection against tuberculosis infection in mice. Proc Natl Acad Sci USA 2000; 97:4204-8.
71. Flynn JL, Goldstein AM, Triebold KJ etal. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1992; 89:12013-17.
72. Van Pinxteren LAH, Cassidy JP, Smedegaard BHC etal. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 2000; 30:3689-98.
73. Bruns H, Meinken C, Schauenberg P etal. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009; 119:1167-77.
74. Stenger S, Hansen DA, Teitelbaum R etal. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998; 282:121-5.
75. Waltz G, Ronacher K, Hanekom W etal. Immunological biomarkers of tuberculosis. Nat Rev 2011; 11:343-54.
76. Plotkin SA. Correlates of protection by vaccination. Clin Vaccine Immunol 2010; 17:1055-65.
77. Paust S, von Andrian UH. Natural killer cell memory. Nat Immunol 2010; 12:500-8.
78. Semple PL, Watkins M, Davids V etal. Induction of granulysin and perforin cytolytic mediator expression in 10-week-old infants vaccinated with BCG at birth. Clin Dev Immunol 2010; 2011:1-9.